Nasdaq:EOLS
Evolus, Inc.
Evolus Inc. (EOLS) is a leading provider of non-invasive aesthetic medical devices driving the anti-aging market with proprietary radiofrequency technology.
Key Metrics
Investment Thesis
Bull Case
Evolus operates in a high-growth anti-aging sector with revenue expanding at a double-digit pace, reaching $266.3M in 2024 from just $148.6M in 2022. The company's proprietary technology platform offers significant pricing power and recurring revenue potential through consumable sales. Aggressive share issuance has preserved liquidity to fund growth initiatives without increasing debt burdens.
Bear Case
The stock is heavily weighted by a massive retained earnings deficit of -$609.4M and negative cash flow from operations, signaling structural profitability issues. With total liabilities exceeding assets significantly, the company remains vulnerable to interest rate hikes or a slowdown in elective medical procedures. Investors should avoid the stock until consistent positive operating income is demonstrated.
About Evolus, Inc.
Evolus Inc. is a global medical device company focused on non-invasive aesthetic procedures, primarily serving dermatologists and plastic surgeons with its proprietary Ellevate™ platform. The company operates in the growing anti-aging and body contouring markets, offering devices like the Venus® VelaSmooth and Ellevate™ that utilize radiofrequency technology to treat skin laxity and fat. With revenue reaching $266.3M in 2024, the firm aims to expand its footprint through strategic acquisitions and international growth while navigating significant debt obligations.
Analysis
Management Discussion
Despite revenue growth to $266.3M, the company continues to report a net loss of -$50.4M, primarily due to elevated general and administrative expenses totaling $198.0M. Cash flow from operations was negative at -$18.0M, offset partially by $51.2M in common share issuances which helped balance financing cash flows. The widening operating deficit suggests the company is prioritizing market expansion over short-term profitability.
Industry Overview
The non-invasive aesthetic medicine industry is experiencing rapid expansion as consumers seek less invasive alternatives to traditional surgery for anti-aging treatments. Regulatory bodies like the FDA and European Commission are increasingly scrutinizing marketing claims, creating a barrier to entry that favors established players with robust IP portfolios. Market consolidation is expected as smaller competitors struggle to match the technological depth of incumbents like Evolus.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $148.6M | $202.1M | $266.3M |
| Cost of Revenue | $55.9M | $61.6M | $84.0M |
| Gross Profit | $92.7M | $140.5M | $182.3M |
| Operating Expenses | $158.1M | $189.8M | $216.7M |
| Operating Income | $-65.3M | $-49.2M | $-34.4M |
| G&A | $141.8M | $164.9M | $198.0M |
| Stock-Based Comp | $10.8M | $16.5M | $22.3M |
| D&A | $3.7M | $5.1M | $5.3M |
| Depreciation | — | — | $1.2M |
| Amortization | $3.4M | $4.1M | $4.1M |
| Other OpEx | $16.2M | $24.8M | $18.7M |
| Non-Operating Income | $-9.0M | $-12.3M | $-15.3M |
| Interest Expense | $9.1M | $13.8M | — |
| Pre-Tax Income | $-74.3M | $-61.5M | $-49.8M |
| Income Tax | $95.0K | $176.0K | $664.0K |
| Continuing Ops | $-74.4M | $-61.7M | $-50.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-74.4M | $-61.7M | $-50.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-74.4M | $-61.7M | $-50.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $100.8M | $112.4M | $151.3M |
| Cash & Equivalents | $53.9M | $62.8M | $87.0M |
| Accounts Receivable | $22.4M | $30.5M | $47.7M |
| Inventory | $18.9M | $11.0M | $12.2M |
| Other Current Assets | $5.6M | $8.1M | $4.5M |
| Long-Term Assets | $77.2M | $76.6M | $81.2M |
| PP&E (Net) | $2.6M | $2.1M | $3.2M |
| Intangibles | $48.6M | $47.1M | $48.8M |
| Goodwill | $21.2M | $21.2M | $21.2M |
| Operating Leases | $1.9M | $5.8M | $7.2M |
| Other LT Assets | $2.8M | $409.0K | $858.0K |
| Total Assets | $178.0M | $189.0M | $232.6M |
| Current Liabilities | $46.5M | $48.3M | $63.0M |
| Accounts Payable | $8.9M | $4.3M | $9.2M |
| Current Leases | $1.3M | $1.4M | $1.7M |
| Deferred Revenue | $9.0M | $11.0M | $14.5M |
| Other Current Liab | $2.4M | $-2.2M | $-3.2M |
| Long-Term Liabilities | $113.0M | $161.4M | $164.1M |
| LT Operating Leases | $1.2M | $4.8M | $6.8M |
| Other LT Liab | $111.8M | $156.6M | $157.3M |
| Total Liabilities | $159.5M | $209.7M | $227.0M |
| Shareholders' Equity | $18.5M | $-20.7M | $5.5M |
| Paid-In Capital | $516.1M | $538.7M | $615.8M |
| Retained Earnings | $-497.3M | $-559.0M | $-609.4M |
| AOCI | $-337.0K | $-427.0K | $-905.0K |
| Total L&E | $178.0M | $189.0M | $232.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-74.4M | $-61.7M | $-50.4M |
| Non-Cash Adjustments | $-20.3M | $11.7M | $11.7M |
| Working Capital Changes | $9.8M | $16.0M | $20.7M |
| Cash from Operations | $-84.9M | $-34.0M | $-18.0M |
| Capital Expenditures | $1.6M | $473.0K | $1.5M |
| Cash from Investing | $-2.9M | $-1.6M | $-4.8M |
| Debt Issuances | — | $50.0M | $0 |
| Cash from Financing | $-4.1M | $44.6M | $47.4M |
| FX Effect | $-337.0K | $-90.0K | $-478.0K |
| Net Change in Cash | $-92.3M | $8.9M | $24.1M |
| Beginning Cash | $146.3M | $53.9M | $62.8M |
| Ending Cash | $53.9M | $62.8M | $87.0M |
Frequently Asked Questions
How does Evolus, Inc. make money?
Revenue streams are driven by hardware sales of Ellevate™ and Venus® platforms, recurring service revenue from consumables like applicators and gels, and licensing fees for intellectual property used in global markets.
What are the main risks for EOLS?
The company faces substantial liquidity risks with $227M in total liabilities versus only $5.5M in shareholders' equity, creating a fragile capital structure. Persistent operating losses of -$50.4M in 2024 indicate ongoing profitability challenges that could deter new institutional investors. Dependence on key distributors and potential regulatory changes in the medical device sector pose additional operational threats.
What is EOLS's competitive advantage?
Evolus holds strong patent protection on its non-invasive radiofrequency technology, creating a durable moat against generic competitors. The company benefits from high switching costs as practitioners build specialized training around their proprietary platforms. A global distribution network ensures broad market penetration across North America and Europe.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.